Kintor's PhaseII U.S. trials for pyrilutamide and the process of pharmaceutical drugs coming to market, with a reply from someone who has just ordered 500mg of Pyrilutamide to start their own phasetrials.
GT20029 showed significant hair growth and safety in phaseIItrials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.
The conversation discusses GT20029, a drug in PhaseIItrials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.
Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese PhaseIII trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.
Hope Medicine received a $28M investment for HMI-115, a monoclonal antibody in phaseIItrials for treating androgenetic alopecia. Some users are skeptical about its effectiveness, while others find the investment and trial results encouraging.